Clinical Trial Update: Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating sacituzumab govitecan for metastatic salivary gland and thyroid cancers (SG-SGTC) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Cancer
• Thyroid Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Salivary Gland Cancer, Thyroid Cancer | Phase 2 | Status: RECRUITING